Open Access
CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(09): E1445-E1446
DOI: 10.1055/a-1521-4912
Editorial

Can innovation in endoscopic therapy alter clinical outcomes in patients with familial adenomatous polyposis?

Monique E. van Leerdam
1   Department of Gastroenterology and Gastro-intestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
2   Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
,
Andrew Latchford
3   Polyposis Registry, St. Marks’s Hospital, Harrow, United Kingdom
4   Department of Surgery and Cancer, Imperial College London, London, United Kingdom
› Author Affiliations
Preview

Familial adenomatous polyposis (FAP) is a rare autosomal dominant inherited disease caused by a pathogenic mutation in the APC gene with a prevalence of about 1 in 8500 to 10,000 births [1]. Patients with “classical FAP” do have a typical phenotype and develop 100 to 1000 adenomas throughout the colon. If left untreated, colorectal cancer will occur at a median age 35 to 45 years. Prophylactic surgery, usually either resection of the colon with an ileo-rectal anastomosis (IRA) or resection of the colon and rectum with an ileo-pouch anal anastomosis (IPAA), is offered to mitigate this risk of cancer. Timing and type of prophylactic surgery depends on the number, size, and histology of the adenomas and should be personalized.



Publication History

Article published online:
23 August 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany